BioBusiness


Audited by PwC

BioBusiness sales were 5% lower in DKK and 12% lower in LCY compared to 2009. Divestment of noncore activities in the microorganism business in 2009 and lower sales of biopharmaceutical ingredients (BPI) were the main reasons for the decrease. Organically, BioBusiness sales were 10% lower compared to 2009.          

Microorganisms

Microorganism sales were up by 3% in DKK and down by 4% in LCY compared to 2009. The total consolidated sales growth impact in 2010 from the divestment of the turf and landscape business in July 2009 and the acquisition of Brazilian bioagriculture company Turfal in August 2010 was approximately minus 4 %-points. Sales to the bioagriculture (BioAg) and wastewater treatment industries increased, whereas microorganism sales to the institutional & household cleaning industry were lower compared to 2009, partly explained by ongoing product pruning.

Biopharmaceutical ingredients

Biopharmaceutical ingredient sales were down by 21% in DKK and by 28% in LCY compared to 2009. The decrease was caused by lower sales of Recombumin® and cell culture ingredients throughout the year and also by the absence of plectasin sales in the fourth quarter of 2010 compared to the same quarter of 2009. The BPI industry is subject to substantial quarterly variations in sales patterns, as sales comprise a small number of transactions of relatively large value.

My Report

0 pages added

MyReport Videos
Acquiring EMD/Merck Crop BioScience will make Novozymes a strong player within biofertility solutions.
Acquisition of EMD/Merck Crop BioScience
Acquisition of EMD/Merck Crop BioScience
Thomas Videbæk, BioBusiness
Novozymes’ bioagriculture business up-close

SEE ALL VIDEOS
A platform for growth in agriculture
With one acquisition finalized and another pending customary regulatory approval, 2010 was the year when Novozymes accelerated building a platform for strong growth in the agricultural market...
CLICK TO READ MORE... 
FIVE-YEAR SALES DEVELOPMENT IN BIOBUSINESS
DKK million
FusionCharts.
Microorganisms
Biopharmaceutical ingredients